



FICPI SWEDEN

FICPI SWEDEN is the Swedish part of FICPI which is an international organization, with members from more than 80 countries. FICPI works for patent and trademark attorneys in the free profession, with issues relating to their daily work as well as IP law issues on a global scale.

The membership in FICPI SWEDEN, which is a prerequisite for membership in the international federation of FICPI, provides a global network of IP professionals, and a possibility to understand and participate in the development of IP law throughout the world.

FICPI SWEDEN runs regular seminars in Sweden focusing on current issues and trends in IP. The speakers are predominantly FICPI colleagues from other countries, within and outside Europe.

The seminars are open for all, but FICPI members enjoy a reduced registration fee.

Seminar on IP Aspects of Life Sciences and MedTech

Lund Thursday 22 May 2014

Attractive price: 3,000 SEK for whole day seminar,
including lunch and light buffet

Price for FICPI members: 2,000 SEK

Venue:

Medicon Village, Scheelevägen 2, Lund,
www.mediconvillage.se

Hotels:

There are a number of hotels in Lund, the closest one is Elite Hotel Ideon at Ideon Gateway in Lund, Scheelevägen 27, 223 63 Lund, Tel: +46 (0)46 287 11 00, www.elite.se/Lund
Attendees are expected to book hotel rooms themselves.

Registration:

By email to: info@ficpisweden.se

A short email indicating your contact information is enough.

We will confirm shortly and send you an invoice in due course.



Image courtesy of Renijth Krishnan / FreeDigitalPhotos.net



FICPI SWEDEN



At Medicon Village the entire value chain, from researchers to innovators and businessmen, will work together under a single flag to create value for people's health and wellbeing. Different skills and knowledge brought together through collaboration create growth, and good ideas that are born out of everyday meetings can make the difference for tomorrow's patients. The work conducted at Medicon Village will be characterized by consideration to the smallest of details and participation in the largest of undertakings. The smallest of companies can enjoy the benefits of a large company's resources by being part of a larger community; and new possibilities are created in the interface and collaboration between regional organizations, universities and the business community.

The total area available for letting within Medicon Village amounts to around 80,000 m², of which laboratories account for about 30,000 m². It is estimated that activities involving the employment of around 500 persons will be established within the facility during the initial phase. Later on, when the plan has been fully executed, the activities within Medicon Village are expected to provide a total of around 1,000 positions of employment.

Together with the Biomedical Centre in Lund (BMC), the Clinical Research Centre in Malmö (CRC) and Medical Malmö, as well as the new research facilities ESS and the MAX IV laboratory, Medicon Village is establishing an infrastructure of world class and thus providing a huge lift to, and enhancing the attractiveness of, the entire region, which is characterized by its internationally acknowledged role in the area of research into, among other things, nanotechnology, cleantech, food and medicine. Through the new strong research infrastructure in northern Lund - Medicon Village, MAX IV and ESS – Sweden's and Denmark's roles within the area of research are further enhanced, and a European role model is established.





FICPI SWEDEN





FICPI SWEDEN

Program – IP Aspects of Life Sciences and MedTech,

Thursday 22 May 2014

at Medicon Village, Scheelevägen 2, Lund

09.30 –10.00 Registration and coffee

10.00 – 10.10 Welcome address Lennart Karlström, President, FICPI Sweden
Introduction Jan Nilsson and Lars Thyresson, FICPI Sweden

10.10 - 10.30 Medicon Village

Mats Leifland, Lund, Sweden
CEO Medicon Village AB



Medicon Village is a life science village for research, innovation and business. The presentation will describe the Medicon Village concept, which is built on triple helix collaboration between academia, industry and the public sector. Medicon Village provides a venue for exchange of ideas. We believe that interdisciplinary exchange is a key driver creating growth. As part of Medicon Village you belong to a community dedicated to creating value for people's health and well-being. Around 90 organizations are located at Medicon Village, and more than 950 persons have their daily workplace at the site.

**10.30 – 11.10 The significance of IPR within the Immunotechnology
Department of Lund
IPR and Cancer Research – do's and don'ts**

Carl Borrebaeck, Lund, Sweden
Pro Vice-Chancellor for Innovation,
Professor, Department of Immunotechnology



The Department of Immunotechnology carries out research and higher education in research areas spanning from advanced technology developments to biomedicine. The presentation outlines the main research areas within oncology, allergy and antibody engineering, using advanced technologies developed in-house. The application of advanced technologies to solve complex biomedical challenges has taken the department to the forefront in several of the described research areas and has resulted in a number of spin-out companies.

11.10 – 11.20 Break



FICPI SWEDEN

11.20 - 12.00 The MAX IV: A light source for the future

Yngve Cerenius, Lund, Sweden
Project Coordinator - MAX IV Beamline Project



When becoming operational for users June 21, 2016 the MAX IV facility will be the lowest emittance synchrotron light source in the world. The low emittance gives outstanding performance regarding brightness and coherence of the synchrotron light thereby enabling entirely new science. In this presentation Yngve will give a brief technical introduction to this new light source. Second, describe the already funded beamline program which today consists of 13 Swedish as well as internationally funded beamlines. Yngve will give an impression of the new possibilities these beamlines will provide to the user community, academic or commercial. Thirdly, MAX IV will also be the working place for some 250 staff members and will when in full operation be visited annually by some 2500 scientist. Thus it will in addition to provide scientist these excellent new opportunities have a significant impact on the regional economy.

12.00 - 13.15 Lunch

**13.15 – 14.00 Challenges in Protecting Biotechnology and
Pharmaceutical Inventions – A Canadian Perspective**

Santosh K. Chari, Toronto, Canada
Patent Agent at the law firm Cassels & Graydon LLP (Blakes)



The protection of life science related inventions has become a very complex process and navigating the often diverging national law requirements poses enormous hurdles for patent applicants. A body of case law over the past few years in Canada highlights some of these challenges. This talk will provide some insights into the potential pitfalls for patent applicants in Canada and into avoidance measures that need to be taken early on in the patent application process.

**14.00 – 14.45 IP case law, preliminary injunctions, in LS/MedTech and
strategies**

Rikard Roos, Sweden, Lund
Senior Partner and European Patent Attorney
at Ström & Gulliksson AB





FICPI SWEDEN

Mattias Malmstedt, Lund, Sweden
Attorney-at-law, Member of the Swedish Bar Association,
Partner at Advokatbyrån Gulliksson ,



An infringement is often related to several jurisdictions and IP Case law and procedural rules differ from country to country. Are there any reason for choosing venue and do you have an option to choose a certain desirable venue? What should you consider when developing a cross boarder injunction strategy? Rikard and Mattias will give some examples from case studies/ law in this field.

14.45 – 15.15 Coffee/Tea break

15.15 – 16.00 DNA/gene patenting after the Myriad decision

Roberto Pistolesi, Milan, Italy
Partner and European Patent Attorney at
Dragotti & Associati international IP attorneys



On June 13, 2013, the United States Supreme Court ruled that genes or other naturally-occurring pieces of DNA are patent ineligible subject matter; however, according to the Court, cDNA does not present the same obstacles to patentability. Comments on the decision have ranged from calling it a victory to a disaster, and everything in between, often forecasting dire consequences both for proponents and opponents of so-called "gene patents". But where is the truth? Although the full implications of Myriad case will likely take years to resolve, some of the possible consequences of the decision will be discussed and compared to the European scenario, where DNA-patenting is regulated by the EU Biotech Directive 98/44/EU of July 6, 1998.

16.00 - 16.15 Final address

16.15 - 17.30 Mingle and light buffet at Medicon Village



We reserve the right to any program changes.



FICPI SWEDEN

SPEAKERS

Seminar on IP Aspects of Life Sciences and MedTech

Mats Leifland

CEO Medicon Village AB

Mats has a Bachelor's degree in Business & Administration from Lund University and 30 years of experience.

He have had a number of different leading positions. Assistant corporate treasurer in Trelleborg 1989-1995. Started in Peab as CFO in 1995 and Executive Vice President from 1996.

Mats ended his position in Peab in April 2011 and started as CEO, Medicon Village AB.



Carl Borrebaeck

Pro Vice-Chancellor for Innovation,
Professor, Department of Immunotechnology

Dr. Carl Borrebaeck, Ph.D. serves as the Chairman and President at Lunds Universitets Innovationssystem AB. He serves as a Pro Vice-Chancellor for Innovation at Lund University. Dr. Borrebaeck is the Professor at the Department of Immunotechnology at Lund University, Sweden since 1990 as well as Director for the translational cancer center (CREATE Health) in Lund. His scientific focus is biomedical applications of molecules of the immune system, mainly antibodies, and he has more than 300 publications in peer-reviewed journals. He served as the Chief Scientific Officer of BioInvent International AB. He has also started two biotech companies, one is listed at Stockholm Stock Exchange. Dr. Borrebaeck served as the Chairman of Forskarpatent i Syd AB. He is a board member of WntResearch AB, Alligator Bioscience AB, SenzaGen AB, and Ocean Capital. Dr. Borrebaeck also serves as a Member of Scientific Advisory Board at InnovationsKapital. He served as a Director at BioInvent International AB since 1997 until April 25, 2013. Dr. Borrebaeck holds a Doctor of Science, M.Sc. degree; and B.Sc. degree in Biochemistry. He has done a Ph.D. in Applied Chemistry from Lund University.





FICPI SWEDEN

Yngve Cerenius

Project Coordinator - MAX IV Beamline Project

Yngve Cerenius has worked at different positions including Beamline Manager and Industrial Liaison Officer at the Swedish synchrotron, MAX-lab, since 1997. After the decision of funding the new start-of-the-art MAX IV facility was made in 2009, he has been working with the coordination of the processes to build up the experimental stations, at present 13 funded, at MAX IV.



Yngve Cerenius has an MSc in Civil Engineering Physics and a Techn. Lic. in Theoretical Geochemistry from Uppsala University before he started to work with synchrotrons. First at a large facility in Grenoble, France, the European Synchrotron Radiation Facility then at MAX-lab in Lund, Sweden. He has been main or co-author of more than 40 published articles primarily based on different synchrotron radiation techniques.

Santosh K. Chari

Patent Agent at the law firm Cassels & Graydon LLP (Blakes)

Santosh has been practicing in the IP field for over 24 years and holds degrees in biochemistry and chemical engineering. He is a registered Patent Agent in Canada and the USA and advises clients on the protection of intellectual property, including the preparation and prosecution of patent and industrial design applications. He also advises on infringement and validity issues relating to intellectual property and on licensing and patent portfolio management issues. He has expertise in a broad range of technologies, including biotechnology, pharmaceutical and chemical subject matters and medical devices.



Santosh has managed the prosecution of patent and industrial design applications before many intellectual property offices throughout the world and has represented clients of various sizes, including private enterprises and public institutions, such as universities and government departments.



FICPI SWEDEN

Rikard Roos

Senior Partner and European Patent Attorney
at the IP firm Ström & Gulliksson AB



Rikard has a Master Degree in Chemical Engineering and has expertise within the areas of medical devices and medical technology, but also chemistry, such as pharmaceuticals, and physics, such as semiconductors. Rikard has special knowledge in contentious matters before national court and the European Patent Office, such as oppositions, infringement issues, nullity actions, and also mediating, strategic patenting, freedom-to-operate analyses and due diligence.

Prior to joining Ström & Gulliksson, he worked within Research & Development at Big Pharma. Rikard was also elected among Sweden's top 101 Super Talents 2013 by Swedish business magazine Veckans Affärer.

Mattias Malmstedt

Attorney-at-law (Advokat), Member of the Swedish Bar Association,
Partner at Advokatbyrå Gulliksson



Advokat Mattias Malmstedt specialises in patent, trademark, market, design, and copyright law as well as commercial law. First and foremost, Mattias Malmstedt is a litigator in the field of intellectual property and marketing law and appears as legal counsel before Swedish courts of justice, other authorities and arbitral tribunals. He has among other things appeared as a legal counsel in the Supreme Court and in the Appeal Court. He also drafts commercial agreements within the intellectual property area. Mattias Malmstedt helps companies and organizations to develop intellectual property strategies and to exploit, enforce and protect their intellectual property rights.

Mattias Malmstedt has litigated several landmark cases in IP matters, recently many cases in the field of design protection. He has successfully defended IKEA in a number of patent, design patent and copyright cases. He is acting both for IKEA in Sweden and the IKEA Company that owns the IP rights on a global level.

Mattias Malmstedt is the lead counsel and represents Doro AB (listed at Stockholm stock exchange) and is responsible for Doro's global cross border litigation strategy. Doro is i.a. dealing with Medicare and senior mobile devices.

He has successfully represented a R&D company together with his colleague Hans-Anders Odh, against the biggest dairy producer Arla Foods in very unique trade secret litigation, where the highest damage amount ever was made.



FICPI SWEDEN

Mattias Malmstedt has been representing “Big-pharma” and has been the counsel inter alia in cases between Boehringer Ingelheim vs Microdrug AG and ratiopharm AB vs Mundipharma AB relating to trade secret and patent infringement, which cases have been multi jurisdiction cases running in parallel in several countries simultaneously.

Roberto Pistolesi

Partner and European Patent Attorney at
Dragotti & Associati international IP attorneys



Roberto has worked for Fedegari Autoclavi Spa and Nalco from 1994 to 1995 and joined Dragotti & Associati in 1995.

Roberto has an extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 50 cases before the Opposition Divisions or the Boards of Appeal. He also has a wide expertise in multi-national patent litigations, having been involved in more than 50 litigations both in Italy and abroad (mainly USA, UK, Germany and France). In particular, he has been involved in patent litigations concerning the following active principles: alendronic acid, atorvastatin, cefaclor, citalopram, docetaxel, enoxaparin, esomeprazole, phosphatidylserine, gabapentin, irbesartan + HCT, latanoprost, olanzapine, omega-3, omeprazole, montelukast, quetiapine, ramipril, repaglinide, rupatadine, samleterol + fluticasone, and terbinafine. He frequently advises clients on patent strategies and provides infringement and validity opinions.

Roberto has been technical expert of the Court of Milan since 2002, where he assists Judges in patent infringement and/or validity cases.

He has been also adjunct Professor at the "Universita' degli Studi" of Milan since 2011, where he has been teaching a course on chemical patent practice to the students of Chemical Science, Industrial Chemistry and Biotechnology.

Since 2012 he has also been the chairman of FICPI's study and work commission dealing with inventions in the pharmaceutical and biotechnology area.

He frequently lectures on intellectual property both in Italy and abroad. He has published several articles on "Il Sole-24 Ore", "Pharmachem" and "Il Diritto Industriale".

Roberto is Italian patent agent, Italian trademark agent, European patent attorney, and Community trademark attorney. He has a Degree in Bio-Organic Chemistry (Università degli Studi di Milano), and CEIPI diploma on patent litigations in Europe